< br />
MOSCOW, March 29Ultra-fast insulin «Fiasp» produced by the Danish Novo Nordisk is regularly supplied to the Russian market, while its domestic analogues with the same international nonproprietary name (INN) insulin aspart are also available to patients, the Ministry of Industry and Trade reported.
Earlier on Friday, the Kommersant newspaper reported that adult patients with diabetes encountered difficulties in obtaining ultra-fast Fiasp insulin, after the injection of which they can almost immediately eat.
“According to data available from the Ministry of Industry and Trade of Russia, the original drug Fiasp produced by Novo Nordisk (INN insulin aspart) is regularly supplied to the Russian market: the last large supply (more than 90 thousand packages) was in January of this year. At the same time, the drug has several biosimilars at once, including domestically produced ones,” the ministry said.
Among such analogues are “Rinfast” and “Rinfast Nick”, which are produced by the domestic company “Geropharm” (delivery of more than 37 thousand packages in January and 38 thousand in March, respectively), as well as «Rosinsulin aspart R» produced by the Medsintez plant (more than 86 thousand packages in March). The department emphasized that domestic manufacturers have sufficient production capacity to meet the annual needs of the country’s healthcare system.
In addition, all drugs with the INN insulin aspart, including those produced domestically, are widely represented in Russian pharmacies: according to the CRPT, they can be purchased in almost 8 thousand outlets. Also, currently there are recorded remains of medicines with this INN with a total volume of more than 1 million packages.